Inimex Pharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of innate defense regulators (IDRs) that modulate the body's innate defenses without causing inflammation. The company offers IMX942, an IDR product that improves survival, ameliorate tissue damage, and reduce bacterial infections through modulation of innate defenses. Its products are used to treat infections and conditions involving tissue injury; ventilator associated pneumonia, tracheobronchitis, bacteremia, endocarditis, and mucositis; and cancer diseases. Inimex Pharmaceuticals Inc. was founded in 2001 and is headquartered in Burnaby, Canada.